Product review · Updated September 30, 2026
SkinCeuticals Blemish + Age Defense review: the US gel and regional acid story differ
The June 2026 gel declaration, older lotion record and India serum highlights answer different product-identity questions.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
SkinCeuticals’ US ingredient page lists Blemish + Age Defense as an acne serum. A newer US labeling record calls the named preparation a gel, while an older US record calls it a lotion. The India product page tells a five-acid serum story with regional claims. These descriptions offer useful formula context, but they cannot be collapsed into one universally matched bottle.
The official records examined on September 30, 2026 include the full June 2026 US label and a December 2024 predecessor record. The direct US manufacturer product page was unavailable, so its current full description was not assessed. The regional page supplies selected acid highlights rather than complete ingredients. No physical package, assay or underlying eight-week study report was inspected.
In this article
The US listing establishes a named acne serum
The official US salicylic-acid glossary lists Blemish + Age Defense as a salicylic-acid acne serum, with a 30-milliliter size. That is product-specific identity information within an ingredient page. Its surrounding general discussion of salicylic acid is not itself a test of this complete formula. US product listing.
The format guide gives product-role descriptions a place beside percentages. Here, the manufacturer’s serum wording can be retained while the posted labels are described accurately. A glossary entry does not resolve every current ingredient or market-version question, and it does not establish the same product experience as a personally examined bottle. An ingredient page can display several products, but only the named Blemish listing supplies identity evidence here. General statements about the acid cannot fill the absent full US marketing page or establish the performance of the complete gel declared in the separate label.
The June 2026 record identifies a US gel
The June 1, 2026 L’Oreal record identifies Blemish Plus Age Defense Acne Treatment, NDC 82046-558, and a gel category. It declares salicylic acid 1.5% with an acne-treatment purpose. This supplies a full US labeled identity that is more specific than the glossary’s short listing. Newer US label.
The narrative also names the complete inactive portion and carries flammability and dryness warnings. These fields describe the submitted preparation; they do not establish whether a reader’s package carries this exact label. Nor does gel coding erase serum as the manufacturer’s marketing descriptor or prove a particular viscosity.
The newer inactive narrative differs from the older lotion
The newer US inactive list includes tocopherol and sunflower-seed oil. The December 27, 2024 record, NDC 49967-097, describes a lotion and supplies another narrative without those two names. Both records declare a 1.5% salicylic-acid active, but the inactive accounts are not identical. June declaration; December lotion record.
A matching active percentage therefore does not settle the full-formula question. The review does not invent a reformulation date or combine the lists into an unrecorded formula. The Paula’s Choice review offers another market-and-declaration comparison, without providing evidence that these products have equal exposure or comfort. The two records also show why an inactive-list difference should not be reduced to a percentage contest. A declared acne active and the rest of the formula answer different identity questions; neither alone supplies a measured comparison of the finished preparations.
The older record has two polyquaternium numbers
Within the older US record, the inactive narrative names polyquaternium-10. The structured ingredient table instead identifies polyquaternium-69 with a molecular-weight notation. The discrepancy is internal to that label view and remains unresolved here. Neither name is silently corrected to make the source appear consistent. Older narrative and table.
That difference does not authorize a chemistry conclusion or identify which constituent was in an actual package. It shows why a product review should preserve the form of evidence being cited. The ingredient-record guide provides broader context for what full lists and selected descriptions can establish.
The five-acid highlights belong to a regional page
The India/international S11 page highlights salicylic acid 1.5%, dioic acid 2%, LHA 0.3%, glycolic acid 3.5% and citric acid 0.5%. It also supplies oil-free and other formula-positioning claims. These are the page’s named acid highlights, rather than a complete regional inactive declaration. Regional product record.
The regional page even displays international and US size options, which does not resolve the formula match. Its oil-free language is not imported into the June US label, whose narrative includes sunflower-seed oil. The records are compared as published; this review does not infer concentrations for unquantified US inactive ingredients from another market’s panel.
The eight-week headline lacks an examined full report
The regional page describes visible improvements in an eight-week study involving lines, blemishes, clogged pores and skin texture. The examined passage does not supply the underlying report or participant count. Regional evidence summary.
The Dermalogica review offers another serum-evidence reading. Such navigation does not rank the products or supply a missing SkinCeuticals result. The dry-skin guide likewise provides context without extending an appearance endpoint into a universal tolerance claim.
Market and label identity limit the comfort comparison
FDA explains that manufacturer labeling can change and that similar product names may carry different ingredient records. That framework helps keep the newer US gel, older US lotion and regional serum highlights separate. It does not demonstrate which version a reader possesses or settle the old table discrepancy. FDA label context.
The available evidence supports a defined US declaration and a bounded comparison of other published descriptions. The common salicylic-acid name and marketed serum role do not establish equal dryness, performance or personal suitability. Preserving those limits is more informative than assigning one region’s claim to every version of Blemish + Age Defense.
Sources behind this reading
- SkinCeuticals US salicylic-acid glossary: exact Blemish + Age Defense listing ↗US manufacturer ingredient page; product listing only · Checked September 30, 2026
- SkinCeuticals India/international Blemish + Age Defense Salicylic Acid Serum ↗Manufacturer regional product record; not a US full declaration · Checked September 30, 2026
- SkinCeuticals Blemish Plus Age Defense: June 2026 gel record ↗Manufacturer-submitted US OTC labeling record · Checked September 30, 2026
- SkinCeuticals Blemish Plus Age Defense: December 2024 lotion record ↗Manufacturer-submitted US OTC labeling record · Checked September 30, 2026
- FDA: The Over-the-Counter Drug Facts Label ↗Regulator explanation of OTC label fields · Checked September 30, 2026